Recent Finacing
Recent Raise
Pretzel Therapeutics develops mitochondrial-targeted therapies using genome correction, expression modulation, and quality-control platforms; lead PX578 in Phase 1 aims to restore mutant mtDNA polymerase function for POLG/mtDNA depletion syndromes.
